In this episode of The Open Loop, Chay Carter is joined by Ken Mariash, CEO of Sinaptica Therapeutics.

Ken shares how Sinaptica is developing a non-invasive, personalised neuromodulation therapy designed to slow the progression of Alzheimer’s disease by targeting the brain networks involved in memory.

This is a practical conversation about moving beyond amyloid-only thinking and looking at Alzheimer’s as a disease of network dysfunction.

We also explore Ken’s background in medtech, biopharma, and neuromodulation, as well as Sinaptica’s Phase 2 data, pivotal trial plans, reimbursement strategy, and vision for biomarker-led Alzheimer’s care.

Key takeaways:

🔹 Why Alzheimer’s may need to be understood as a disease of network dysfunction
🔹 How Sinaptica is combining TMS and EEG to personalise neuromodulation
🔹 Why traditional TMS can be limited by targeting and dosing uncertainty
🔹 How biomarker-led therapy could help clinicians understand whether treatment is working
🔹 Why non-invasive, personalised brain stimulation could become part of the future Alzheimer’s treatment pathway

Guest: Ken Mariash

CEO of Sinaptica Therapeutics

LinkedIn: https://www.linkedin.com/in/kenmariash/

Host: Chay Carter

Founder, Carter Sciences | Co-Founder, Reccy Neuro

LinkedIn: https://www.linkedin.com/in/chay-carter/

The Open Loop is a podcast exploring the people, companies, and ideas shaping the future of neurotechnology.

🔔 Subscribe for weekly conversations with the founders, researchers, and operators building what comes next in brain health, medicine, and technology.

If you enjoyed this episode, please subscribe, leave a review, and share it with someone interested in the future of neurotechnology.

New episodes of The Open Loop drop every week.

Sponsor:
This episode is sponsored by ReccyNeuro — the home of neurotech. Jobs, companies, investors, events, Cortex industry intelligence, and specialist resources for the neurotech market.

Learn more about ReccyNeuro here: https://neuro.reccy.dev/